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Abstract: Follicular lymphoma is predominantly managed as a chronic disease, with intermittent 
chemo/immunotherapy reserved for symptomatic progression. It is considered incurable with 
conventional treatments, and current therapeutic options are associated with significant toxicities 
that are especially limiting in older patients. Bortezomib (PS-341; Velcade®), a first-in-class 
drug targeting the proteolytic core subunit of the 26S proteasome, has emerged as a therapeutic 
alternative in follicular lymphoma, with promising preclinical data and efficacy in patients with 
other hematological malignancies. Several clinical trials were conducted with bortezomib for 
the treatment of non-Hodgkin’s lymphoma. As a single agent, overall responses in follicular 
lymphoma varied greatly (16%–41%), with weekly bortezomib showing less neurotoxicity than 
twice-weekly regimens, but with concern about decreased responses.   Combination with rituximab 
was projected to improve the efficacy of bortezomib, but this resulted in increased toxicities 
and questionable added benefit. Although the largest Phase III study in follicular lymphoma 
of bortezomib plus rituximab versus rituximab alone demonstrated a significant progression-
free survival difference, the absolute difference was small (12.8 months versus 11 months). 
Combining bortezomib with established regimens, such as rituximab plus cyclophosphamide, 
doxorubicin, vincristine, and prednisone (R-CHOP), rituximab, cyclophosphamide, vincristine, 
and prednisone (R-CVP), or rituximab-bendamustine also did not show definite benefit, and 
many of these studies did not meet their primary endpoint when bortezomib failed to improve 
responses or survival to the degree anticipated. In a disease where the goal of treatment is 
palliative and affected patients often have other medical and treatment-related comorbidities, 
decisions regarding therapies which carry risks of additional toxicities must be considered 
carefully. Conclusive evidence of the ability of bortezomib to improve patient outcomes 
meaningfully and to justify the added toxicity is lacking, but limitations in cross-trial comparisons 
are recognized. Large randomized trials and investigations of combinations with promising novel 
targeted agents will aid in determining the role of bortezomib, if any, in the future treatment 
of follicular lymphoma.
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Introduction
Follicular lymphoma, an indolent lymphoma of germinal center B cells, is the second 
most common subtype of non-Hodgkin’s lymphoma in the United States, with nearly 
14,000 new cases diagnosed annually.1,2 Patients typically present with asymptomatic 
enlarged superficial lymph nodes or nonspecific complaints from bulky deeper lymph 
nodes, but unusual presentations with primary involvement of the gastrointestinal 
tract,3,4 skin, or other extranodal sites have been described.5 A minority of patients 
with follicular lymphoma are diagnosed with early stage I/II disease and may be cured 
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by radiotherapy.6–8 However, nearly 70%–85% of patients will 
present with advanced disease, including lymphatic involve-
ment on both sides of the diaphragm (Stage III), or diffuse 
involvement of extralymphatic tissues (Stage IV). Asymp-
tomatic patients with stable disease can be observed closely 
without treatment, given insufficient evidence at present to 
indicate a survival advantage for early intervention,9–11 but 
a majority of patients will eventually need therapy. Despite 
persistent progress in available chemotherapy and immuno-
therapy, follicular lymphoma is still considered incurable by 
conventional treatment.
Follicular lymphoma is managed as a chronic disease, 
with patients intermittently requiring therapy for symptom-
atic progression of disease. When patients relapse, treatment 
options include observation for asymptomatic patients, 
immunotherapy alone (ie, rituximab), immunotherapy with 
combination chemotherapy, radioimmunotherapy (conjugate 
antibody with radioisotope), or, rarely, autologous or alloge-
neic hematopoietic cell transplantation. If available, enroll-
ment in a clinical trial is the preferred option. Each choice 
of therapy has varying degrees of toxicities with associated 
effects on quality of life and risk of treatment-related death. 
Considering the median age at diagnosis is 61–63 years,1,12 
these risks can limit treatment options in a population with 
medical comorbidities and functional impairment. In addi-
tion, as overall survival in follicular lymphoma increases,13 
significant concerns are emerging regarding long-term cumu-
lative toxicities from treatment. These limitations create a 
need for the development of well tolerated, novel, targeted 
therapeutic options for relapsed follicular lymphoma.
The proteasome inhibitors have become an area of active 
research in the treatment of non-Hodgkin’s lymphoma. 
Bortezomib (PS-341; Velcade®, Millennium Pharmaceuticals 
Inc, Cambridge, MA) was the first proteasome inhibitor to be 
approved by the US Food and Drug Administration, initially 
for use in multiple myeloma and later in relapsed mantle 
cell lymphoma.11–13 Its mechanism of action, especially its 
potential effect on B cell lymphoma 2 (Bcl-2) led bortezomib 
to become a favorable candidate for exploration as a single 
agent or as part of combination therapy for relapsed follicular 
lymphoma.
Bortezomib: mechanism of action
Bortezomib was a first-in-class drug designed to target 
the ubiquitin-proteasome pathway, the regulatory path-
way for intracellular protein degradation in eukaryotes. 
S  pecifically, bortezomib is a potent boronic acid inhibitor 
of the 20S proteolytic core subunit of the 26S proteasome. 
U  biquitinized (“tagged”) proteins are targeted for destruc-
tion by the proteasome; these tagged substrates can include 
cyclins and cyclin-dependent kinases, transcription factors, 
tumor suppressors (ie, p53), and misfolded or adversely 
mutated proteins. The timed destruction of these key regula-
tory proteins enables cells (normal or neoplastic) to control 
cell viability, proliferation, cell cycle progression, and in 
the case of malignancy, the ability to metastasize through 
expression of genes involved in migration, angiogenesis, and 
adhesion.14–16 Because of the role of the ubiquitin-proteasome 
pathway in cell survival, proteasome inhibition is proposed 
to have powerful antineoplastic properties by both prevent-
ing tumor growth and metastasis, and increasing apoptosis 
of the malignant clone.15
The first preclinical studies involving PS-341   (bortezomib) 
were conducted in a wide variety of cell lines and murine 
models, including solid tumors (prostate, breast, lung) and 
hematologic malignancies, and confirmed its ability to 
  target the proteasome with resultant cell cytotoxicity, as 
well as arrest of cell cycle progression leading to   subsequent 
apoptosis.17–19 Additional in vitro and in vivo studies 
  demonstrated an antagonistic effect of proteasome inhibitors 
on specific controllers of apoptosis, including nuclear factor 
kappa B (NF-κB), Bcl-2, and caspases.15
Bcl-2, an antiapoptotic protein, is overexpressed in 
approximately 85% of cases of follicular lymphoma as a 
result of the t(14;18) translocation characteristic of this 
malignancy, thereby making Bcl-2 an interesting target 
for proteasome inhibitors.20,21 In vitro work demonstrated 
that cell lines treated with proteasome inhibitors induced 
phosphorylation and degradation of Bcl-2, therefore pre-
venting the protective function of the protein with resultant 
apoptosis.22,23 NF-κB is another transcription factor that 
controls expression of genes involved in proliferation and 
inhibition of apoptosis in part by downstream activation 
of the Bcl-2 family. It can be constitutively activated in 
hematologic malignancies or accumulate in chemotherapy-
treated patients as a mechanism of drug resistance and so is 
another exciting target in the treatment of non-Hodgkin’s 
lymphoma.24,25 Proteasome inhibition can stabilize the 
intracellular inhibitor of NF-κB, IκB, thereby abrogating the 
deleterious effects of NF-κB on proliferation, cell adhesion, 
angiogenesis, and resistance to inducers of apoptosis.14,26 
Considering the classic pathobiology of disordered apoptosis 
in indolent lymphomas, these targets have been of particular 
interest in follicular lymphoma, and provided support for 
the promising therapeutic potential for bortezomib and other 
proteasome inhibitors.
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Single-agent clinical trials
As bortezomib gained promise in the hematologic 
malignancies for its treatment of refractory multiple 
myeloma, trials of its use in the non-Hodgkin’s lymphomas 
were   progressing. Early Phase II studies of single-
agent bortezomib in relapsed/refractory non-Hodgkin’s 
lymphoma revealed strikingly varied efficacy, in that chronic 
lymphocytic leukemia was almost uniformly refractory to 
bortezomib, while mantle cell lymphoma demonstrated 
exciting responses that eventually led to its approval by 
the US Food and Drug Administration for mantle cell 
lymphoma. In most studies, the results for the other low-
grade lymphomas, including follicular lymphoma, were less 
impressive (summarized in Table 1).27–30 The demonstrated 
differences in response rates between mantle cell lymphoma 
and other non-Hodgkin’s lymphoma, especially considering 
the established inferior overall survival and fewer effective 
chemotherapeutic and/or immunotherapeutic options in 
mantle cell lymphoma, led many to describe patients with 
mantle cell lymphoma separately from other patients with 
non-Hodgkin’s lymphoma. Therefore, our discussion of the 
bortezomib trials reflects this separation of patients with 
mantle cell lymphoma.
One of the first studies of single-agent bortezomib in 
follicular lymphoma, published by Goy et al, was a mul-
ticenter study of 60 patients with relapsed or refractory 
non-Hodgkin’s lymphoma (median 3.5 prior therapies). The 
majority of patients had mantle cell lymphoma (n = 33). 
Patients were treated with bortezomib 1.5 mg/m2 on days 1, 
4, 8, and 11 of a 21-day cycle. Although the overall response 
rate of 44% in the mantle cell lymphoma arm was encourag-
ing, only 19% of the “other” patients with non-Hodgkin’s 
lymphomas responded; results were not specifically reported 
for the five patients with follicular lymphoma who were 
enrolled in the study.28
Another Phase II trial reported the following year, ie, the 
multicenter European trial by Strauss et al, was designed to 
assess the efficacy of single-agent bortezomib in patients with 
non-Hodgkin’s lymphoma. Fifty-one patients were enrolled, 
including 13 patients with follicular lymphoma. Patients were 
treated at a lower dose (1.3 mg/m2) of bortezomib on days 1, 
4, 8, and 11 of a 21-day cycle. Responses occurred in two of 
the patients with follicular lymphoma (overall response rate 
18%), but were not seen until follow-up imaging 3 months 
after conclusion of bortezomib treatments.30 Similar results 
were found by Di Bella et al in a multicenter Phase II trial of 
Table 1 Clinical trials of single-agent bortezomib
Population Dosing schedule Response rates in FL Toxicities reported as percentage of all patients
Neuropathy Other adverse events
Relapsed/refractory 
indolent B cell 
NHL and MCL 
n = 60 (8% FL*) 
Goy et al28
Biweekly:  
bortezomib  
1.5 mg/m2 d 1, 4, 8,  
and 11 of 21-d cycle
ORR: NR 
CR/CRu: NR
Gr 3/4 neuropathy: 5% Gr 3/4 neutropenia: 15% 
Gr 3/4 thrombocytopenia: 49% 
Gr 3/4 Gi toxicity: 22%
Relapsed/refractory 
indolent NHL and MCL 
n = 26 (38% FL) 
O’Connor et al29
Biweekly:  
bortezomib  
1.5 mg/m2 d 1, 4, 8,  
and 11 of 21-d cycle
ORR: 77% 
CR/CRu: 22%
Gr 3/4 neuropathic pain: 0% 
Gr 3/4 neuropathy (sensory): 8%
Gr 3/4 neutropenia: 4% 
Gr 3/4 thrombocytopenia: 27% 
Gr 3/4 Gi toxicity: 3%
Relapsed/refractory 
lymphoma 
n = 51 (25% FL) 
Strauss et al30
Biweekly: 1.3 mg/m2  
on d 1, 4, 8, and 11  
of a 21-d cycle
ORR: 18% 
(All FL responses were  
late PRs occurring  
3 months s/p  
bortezomib) 
CR/CRu: 0%
Gr 3/4 neuropathic pain: 4% 
Gr 3/4 neuropathy (sensory): 2% 
Gr 3/4 autonomic dysfunction: 4%
Gr 3/4 neutropenia: 10% 
Gr 3/4 thrombocytopenia: 43% 
Gr 3/4 Gi toxicity: 16%
Relapsed/refractory 
indolent NHL 
n = 53 (68% FL) 
Di Bella et al31
Biweekly: 1.3 mg/m2  
d 1, 4, 8 and 11  
of a 21-d cycle
ORR: 17% 
CR/CRu: 8%
Gr 3/4 neuropathy: 7% Gr 3/4 neutropenia: 8% 
Gr 3/4 thrombocytopenia: 20% 
Gr 3/4 Gi toxicity: 15%
FL or MCL with  
#3 prior therapies 
n = 26 (65% FL) 
Gerecitano et al33
Weekly: 1.8 mg/m2  
on d 1, 8, 15, and 22  
of a 35-d cycle
ORR: 14% 
CR/CRu: 0%
Gr 3/4 neuropathy (sensory): 4% Gr 3/4 neutropenia: 15% 
Gr 3/4 thrombocytopenia: 8% 
Gr 3/4 Gi toxicity: 0%
Note: *Includes five patients with FL and three patients with transformed FL.
Abbreviations: FL, follicular lymphoma; NHL, non-Hodgkin lymphoma; MCL, mantle cell lymphoma; ORR, overall response rate; CR/CRu, complete response/unconfirmed 
complete response; Gr, grade; d, day; Gi, gastrointestinal; NR, not reported.
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single-agent bortezomib at the 1.3 mg/m2 dose on the same 
twice-weekly schedule for relapsed or refractory indolent 
lymphoma. Thirty-six patients with follicular lymphoma 
were enrolled, and for this subgroup the overall response 
rate was 17%, with one confirmed complete response and 
one unconfirmed complete response, as well as three partial 
responses.31 This was the largest of the single-agent trials, 
by both total number of patients and number of patients with 
follicular lymphoma, and it was the first to report time to 
progression, with a median time to progression for all patients 
of 5.1 (range 0.2–27.7) months.
Much higher response rates were found by O’Connor 
et al using 1.5 mg/m2 twice weekly for 2 weeks followed by 
a 1-week break.29,32 Eighteen subjects with follicular lym-
phoma were evaluable for response, with an overall response 
rate of 50% and a complete response of 22%, similar to the 
results seen in mantle cell lymphoma. However, the time to 
treatment response was significantly longer in the follicular 
lymphoma group, with a median time to treatment response 
of 11 weeks versus only 4 weeks in mantle cell lymphoma. 
Overall, the median number of cycles received on this trial 
was three, and this may explain the higher response rates 
seen in this trial than in the Goy trial, in which nonrespond-
ing subjects were taken off study after only two cycles of 
bortezomib. More treatment cycles cannot entirely explain 
the increased responses seen by O’Connor et al, because a 
median of 3–4 cycles was administered in the trials reported 
by Di Bella et al and Strauss et al with less impressive results. 
However, the latter two trials used a lower dose of bortezomib 
(1.3 mg/m2 versus 1.5 mg/m2), which could have contributed 
to the lower response rates.30,31
Although bortezomib was generally well tolerated, 
side effects did lead to drug discontinuation. As many as 
33% of subjects in the clinical trials discontinued the drug 
due to adverse events,31 even with the lower bortezomib 
dose of 1.3 mg/m2. Therefore, in an effort to ameliorate 
toxicities, a weekly bortezomib schedule was again studied 
by   Gerecitano et al.33 Bortezomib at 1.8 mg/m2 was given 
for 4 consecutive weeks, followed by a 2-week break for 
each cycle. Twenty-six patients were treated, including 
17 patients with follicular lymphoma. Less   toxicity 
occurred with weekly dosing, but response rates were lower 
than expected. The overall response rate was only 14% 
in the 14 assessable follicular lymphoma patients, with 
no complete responses. The overall response rate for all 
22 evaluable lymphoma patients enrolled was only 18%. 
This was significantly less than the overall response rate of 
50% obtained by the same investigators in the clinical trial 
of biweekly bortezomib discussed above.29 Progression-free 
survival was not different at 4.8 months for twice-weekly 
patients and 6.7 months for weekly patients.33
The weekly versus twice-weekly debate was defini-
tively answered by the Groupe d’Etude Des Lymphomas 
De l’Adulte (GELA) in a randomized Phase II trial   comparing 
single-agent bortezomib on a weekly or biweekly schedule in 
87 patients with relapsed or refractory follicular   lymphoma. 
Subjects were randomized to arm A, ie, 1.5 mg/m2 bortezomib 
administered on days 1, 4, 8, and 11 of a 21-day cycle for 
eight cycles, or to arm B, ie, 1.6 mg/m2 bortezomib adminis-
tered weekly on days 1, 8, 15, and 22 of a 35-day cycle for six 
cycles. A predefined interim efficacy analysis demonstrated 
insufficient response in the weekly dosing arm, so it was 
closed to enrollment. Overall response rates were reported 
as 32% in arm A and 23% in arm B,34 so twice-weekly bort-
ezomib was recommended for further study. However, given 
the low overall response rates from single-agent bortezomib 
in follicular lymphoma, the focus had already shifted toward 
the combination of bortezomib with rituximab or other 
chemoimmunotherapy in the hope of improving the efficacy 
of bortezomib in f  ollicular lymphoma.
Bortezomib plus rituximab
Bortezomib plus rituximab was an attractive area of study 
because of the differing mechanisms of action and different side 
effect profiles, and demonstrated single-agent activity for both 
agents in follicular lymphoma. In vitro and in vivo murine stud-
ies demonstrated additive effects on response from the combi-
nation of bortezomib and the anti-CD20 monoclonal antibody, 
rituximab.35–37 In addition, a mantle cell lymphoma murine 
model showed statistically significant improvement in overall 
survival in mice treated with bortezomib + rituximab compared 
with mice that received either drug alone, although no specific 
data were available in mice with follicular lymphoma.37 It has 
been hypothesized that bortezomib may overcome   rituximab 
resistance by upregulating CD20 expression in rituximab-
  resistant patients characterized by low CD20 expression.38 Based 
on the preclinical data, results from trials of bortezomib plus 
rituximab were anticipated not only for the response potential in 
patients with relapsed or refractory non-Hodgkin’s lymphoma, 
but also in the hope of a less toxic alternative to conventional 
chemotherapies. Selected bortezomib plus rituximab combina-
tion trials are represented in Table 2.
One of the first studies of this combination again exam-
ined the weekly versus twice-weekly bortezomib schedule, 
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but this time in combination with rituximab. In 2009, 
de Vos et al reported a multicenter randomized Phase II 
study of weekly bortezomib (1.6 mg/m2) or twice-weekly 
bortezomib (1.3 mg/m2), each combined with rituximab 
for relapsed/refractory follicular lymphoma or mantle cell 
lymphoma. Seventy of the 81 patients enrolled had folli-
cular lymphoma. The overall response rate for the patients 
with follicular lymphoma was 48% in arm A (twice-weekly 
  bortezomib) and 39% in arm B (weekly bortezomib). This 
higher response rate was seen in arm A, even though far 
fewer patients completed all protocol-driven therapy than in 
arm B (39% versus 80%).36 Surprisingly, only a   minority of 
discontinuations was attributed to adverse events (10% in 
arm A and 3% in arm B). The primary reasons for discon-
tinuation of therapy were progressive disease (arm A, 24%; 
arm B, 10%) or patient/investigator decision (arm A, 22%; 
arm B, 5%). However, it is possible that toxicities were the 
cause of some of the patient/investigator decisions to with-
draw, because the incidence of grade 3/4 adverse events 
(54% versus 35%) and the incidence of serious adverse 
events (29% versus 15%) were all higher on the biweekly 
(arm A) regimen. These results suggest that, in combination 
with rituximab, weekly bortezomib was better tolerated, but 
with lower response rates than biweekly dosing.
In 2010, Agathocleous et al published their results of 
a Phase I/II multicenter trial in the UK also examining 
the regimen of rituximab with either twice-weekly 
(arm A) or weekly (arm B) bortezomib in non-Hodgkin’s 
lymphoma patients. After preliminary results from the 
other bortezomib trials discussed above, the trial proceeded 
directly to Phase II randomization after only seven patients 
were enrolled in the Phase I study. Though the randomized 
dosing regimens of weekly versus twice-weekly bortezomib 
mirrored the study by de Vos et al, the total number 
of cycles and the rituximab regimens differed slightly 
between the trials. A total of 42 patients were randomized 
to the Phase II study, including 13 patients with follicular 
lymphoma who demonstrated a histologic-specific overall 
Table 2 Clinical trials of bortezomib in combination with rituximab
Population Bortezomib dosing  
schedule
Response in FL pts Toxicities reported as percentage of patients
Gr 3/4 neuropathy Other AEs (GR 3/4)
RCT: relapsed/refractory  
FL or MZL 
n = 81 
(86% FL) 
de vos et al36
Arm A: biweekly  
bortezomib 1.3 mg/m2  
n = 41
Arm B: weekly  
bortezomib 1.6 mg/m2 
n = 40
ORR: 48%
 
 
ORR: 37%
Neuropathy  
NOS: 10%
 
Neuropathy  
NOS: 5%
Neutropenia: 10% 
Thrombocytopenia: 10% 
Gi toxicity: 27%
Neutropenia: 3% 
Thrombocytopenia: 0% 
Gi toxicity: 20%
RCT: relapsed/refractory  
FL, MCL, or WM 
n = 42 (31% FL) 
Agathocleous et al39
Arm A: biweekly  
bortezomib 1.3 mg/m2  
n = 21
ORR for all tumor types  
67% in each arm; 
ORR 53% for FL  
(ORR for FL per arm NR)
Neuropathy  
NOS: 14%
Neutropenia: 24% 
Thrombocytopenia: 29% 
Gi toxicity: 15%
Arm B: weekly  
bortezomib 1.6 mg/m2 
n = 21
Neuropathy  
NOS: 5%
Neutropenia: 14% 
Thrombocytopenia: 10% 
Gi toxicity: 0%
Relapsed/refractory  
MCL or FL 
n = 25 (44% FL) 
Baiocchi et al41
Biweekly  
bortezomib*  
1.3–1.5 mg/m2
ORR: 55%  
CR/CRu: 45% 
PFS: 11.5 mo
Neuropathy (sensory): 36% 
Neuropathy (motor): 4% 
Autonomic neuropathy: 12%
Neutropenia: 20% 
Thrombocytopenia: 20% 
Gi toxicity: 0%
RCT: relapsed/refractory  
Gr ½ FL 
n = 676 pts (100% FL) 
Coiffier et al42
Weekly bortezomib  
1.6 mg/m2 d 1, 8, 15,  
22 of 35-day cycle 
37.5 mg/m2 
n = 336
ORR: 63% 
CR/CRu: 25% 
PFS: 12.8 mo
Neuropathy (sensory): 3% Neutropenia: 11% 
Thrombocytopenia: 3% 
Gi toxicity: 11%
Rituximab only arm 
375 mg/m2 
n = 340
ORR: 49% 
CR/CRu: 18% 
PFS: 11 mo
Neuropathy (sensory): 0% Neutropenia: 4% 
Thrombocytopenia: ,1% 
Gi toxicity: ,1%
Notes: *After first 11 patients, the bortezomib dose was decreased from 1.5 mg/m2 to 1.3 mg/m2 because seven patients had Grade 3 neurotoxicity. No patients received 
preplanned rituximab-bortezomib maintenance therapy because of toxicity, ,partial response to study drugs, or they proceeded to stem cell transplant. Gi toxicity may 
include diarrhea, nausea, constipation, and vomiting.
Abbreviations:  Gi,  gastrointestinal;  RCT,  randomized  controlled  trial;  FL,  follicular  lymphoma;  MZL,  marginal  zone  lymphoma;  MCL,  mantle  cell  lymphoma;  WM, 
Waldenstrom’s macroglobulinemia; PFS, progression-free survival; ORR, overall response rate; CR/CRu, complete response/complete response unconfirmed; Gr, grade; 
AEs, adverse events; Pt, patient; d, day; NR, not reported; NOS, not otherwise specified; mo, months.
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response rate of 53%.39 The overall response rate of all 
included patients was identical between the arms at 67%, 
but the number of patients with follicular lymphoma was 
small, and differences in responses between arms for this 
subgroup were not reported. Unfortunately, toxicity was 
high, so only 14 of the 42 patients completed therapy 
as scheduled. The large majority of patients (n = 16) were 
discontinued from therapy for drug toxicities (eight for 
neuropathy and the remainder for either gastrointestinal 
toxicity, infection, fatigue, hemorrhage, or unspecified 
cardiac toxicity) or patient choice (n = 4). The remaining 
subjects withdrew because of disease progression (n = 7) 
or for an unknown reason in one patient.40
Baiocchi et al published a Phase II study using an induc-
tion regimen of rituximab plus twice-weekly bortezomib 
(initially 1.5 m/m2 but decreased to 1.3 mg/m2 because of 
neurologic toxicity). The clinical trial included 25 patients 
with relapsed or refractory mantle cell lymphoma or follicu-
lar lymphoma. The overall response rate for the 11 patients 
with follicular lymphoma was 55%, which was similar to the 
other studies of bortezomib plus rituximab.41 Although 
this was a small, nonrandomized, single-institution study, 
this trial was notable for interesting laboratory correlates. 
During cycle 1, subjects received bortezomib alone with 
the addition of rituximab during cycle 2, so that the effects 
of rituximab on proteasome inhibition could be evaluated; 
they found no difference in proteasome inhibition with 
the addition of rituximab. There was also no correlation 
between levels of proteasome inhibition and response to 
the study drugs, although higher inhibition was associated 
with an increased incidence of grade 3 neurotoxicity. In 
contrast, when they evaluated Fcλ gene polymorphisms 
(receptors which bind IgG antibodies) they found that sub-
jects who were heterozygous for the CD32a genotype had 
significantly shorter progression-free survival compared 
with homozygotes. However, this was a small study and 
these findings would need to be confirmed in larger studies. 
The rate of grade 3/4 neurotoxicity (54%) was much higher 
in this protocol than that seen in the trial by de Vos et al, 
and was significantly associated with achieving a complete 
response or partial response. Neurotoxicity limited the toler-
ability of this regimen, and the authors recommended that 
future studies examine once-weekly bortezomib-rituximab 
combinations. Similar to other rituximab-bortezomib com-
bination trials, the study by Baiocchi et al concluded that a 
large randomized trial would be needed to delineate better 
whether the efficacy seen with bortezomib in patients with 
relapsed or even rituximab-refractory follicular lymphoma 
could outweigh the added toxicities which resulted from the 
combination regimen.
In August 2011, the anticipated results of such a trial 
using the better tolerated weekly regimen of bortezomib 
were published. Coiffier et al, on behalf of the LYM-3001-
study investigators, reported the results of a randomized, 
multinational (164 centers in 29 countries) Phase III clinical 
trial which included 676 patients with relapsed or refractory 
follicular lymphoma. Patients were randomized to receive 
rituximab 375 mg/m² on days 1, 8, 15, and 22 of a 35-day 
cycle for cycle 1, and on day 1 only for cycles 2–5, either 
alone or with bortezomib given weekly at 1.6 mg/m² on 
days 1, 8, 15, and 22 of all cycles. Five cycles were planned. 
The primary endpoint was progression-free survival and, at 
the end of a median 33.9 months of follow-up, a significant 
increase in progression-free survival was seen in the bort-
ezomib plus rituximab arm (12.8 months) compared with 
the rituximab only treatment arm (11 months). This also 
coincided with a better overall response rate in the combina-
tion arm versus the rituximab only arm (63% versus 49%, 
respectively).42 However, the safety profiles revealed higher 
rates of grade 3 or higher adverse events, serious adverse 
events, and adverse events leading to withdrawal from the 
study in the patients treated with bortezomib plus rituximab; 
and although the progression-free survival difference was 
statistically longer in the bortezomib plus rituximab arm, 
it was a small absolute difference (less than 2 months) and 
was less than the 33% expected difference prespecified at 
study design. The authors proposed that the combination 
regimen of bortezomib plus rituximab may benefit certain 
subpopulations with adverse prognostic factors, but the 
results of bortezomib in combination with rituximab were 
not as impressive as hoped for, and again attention refocused 
on ongoing trials which explored the potential of bortezomib 
combined with other established chemoimmunotherapy 
regimens.
Combination 
chemoimmunotherapy trials
Preclinical and early Phase I and II trials of single-agent 
bortezomib suggested that chemoresistant malignant 
cells responded to proteasome inhibition, and that there 
could be a synergistic effect from the combination of 
proteasome inhibitors with the cytotoxic effects of other 
chemotherapeutic and immunotherapeutic regimens.43–49 
The complementary mechanisms of action of proteasome 
inhibitors with conventional cytotoxic therapy can occur on 
several levels, including lowering the apoptotic   threshold 
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of the cell by overcoming molecular mechanisms of 
drug resistance (ie, overexpression of NF-κB induced by 
  chemotherapies), downregulation of constitutively active 
signaling proteins involved in proliferation pathways 
(ie, phosphorylated-Akt in the PI3k/akt pathway), and 
inhibiting DNA repair enzymes so that the DNA damag-
ing action of anthracyclines or other agents have greater 
effect.14,37,50,51
Several Phase II studies have been published regarding 
the combination of bortezomib with other chemoimmuno-
therapies in non-Hodgkin’s lymphoma, including follicular 
lymphoma, and selected studies are summarized in Table 3 
(regimens containing rituximab plus cyclophosphamide, 
doxorubicin, vincristine, and prednisone [R-CHOP] and 
rituximab, cyclophosphamide, vincristine, and prednisone 
[R-CVP]) and Table 4 (regimens containing rituximab-
bendamustine.) In 2009, GELA reported on a randomized 
Phase II trial of the addition of biweekly versus weekly 
bortezomib to R-CHOP as initial treatment in CD20+ 
B cell lymphomas. Based on good tolerability, the dose of 
bortezomib was increased in the last 25 patients enrolled 
from 1 mg/m2 to 1.3 mg/m2 in the biweekly dosing and from 
1.3 mg/m2 to 1.6 mg/m2 in the weekly dosing arm. Eleven 
patients with follicular lymphoma were enrolled and the 
complete response/unconfirmed complete response rate in 
follicular lymphoma for the combined arm was 82%. The 
response rate in all subjects appeared higher in the biweekly 
arm (complete response/unconfirmed complete response of 
90% versus 79%), though the study was not designed to 
determine if these differences were statistically different. 
The neurologic toxicities with bortezomib also appeared 
higher in the biweekly bortezomib group and with the higher 
doses of bortezomib. Grade 3 neurologic toxicity occurred in 
70% of patients receiving biweekly 1.3 mg/m2 bortezomib 
versus 0% at the lower dose (1 mg/m2), and in 27% of 
patients receiving weekly 1.6 mg/m2 bortezomib versus 
7% at weekly 1.3 mg/m2. The investigators concluded, in 
line with other available evidence, that dosing of biweekly 
bortezomib in combination with R-CHOP should not exceed 
doses of 1 mg/m2.52,53 Whether lower doses add meaningful 
benefit, especially given the significant side effects that still 
occur at these doses, is questionable and likely part of the 
Table 3 Clinical trials of R-CvP/R-CHOP with and without bortezomib
Population Bortezomib dosing  
schedule
Response rates  
for all patients
Toxicities reported as percentage of patients
Neuropathy Gr 3/4 heme toxicity
Previously untreated patients  
with CD20-positive  
B cell lymphomas 
n = 49 (22% FL) 
Ribrag et al52
Arm A: biweekly bortezomib  
(1.0–1.3 mg/m2) + R-CHOP  
(six cycles) n = 20
 
Arm B: weekly bortezomib 
(1.3–1.6 mg/m2) + R-CHOP  
(six cycles), n = 29
CR/CRu: 90% (18/20)
 
 
 
CR/CRu: 79% (23/29)
25% overall; 71%  
at 1.3 mg/m2 dose
 
 
17% overall; 27%  
at 1.6 mg/m2 dose
Leukopenia:  
35% of cycles  
thrombocytopenia:  
35% of cycles
Leukopenia: 44%  
of cycles  
Thrombocytopenia: 0%
Previously untreated patients  
with low-grade B cell NHL  
n = 513 total 
(54% FL) n = 253  
for R-CHOP 
(55% FL) 
Rummel et al70
R-CHOP versus  
R-bendamustine  
(data presented here  
for the R-CHOP arm only)
CR 30%; Median PFS  
35 months
Paresthesias: 29% Neutropenia:  
46% of cycles
Low-grade B cell NHL  
n = 40 (% w/FL NR) 
Czuczman et al69
R-CHOP (six cycles) ORR: 95%  
CR: 55%
Paresthesias: 12.5%  
(all grade 1)
Neutropenia: 60% 
Thrombocytopenia: 10%
Previously untreated patients  
with FL n = 94 (100% FL) 
Sehn et al54
Weekly bortezomib 
 (1.3 mg/m2) + R-CvP
ORR: 83%  
CR/CRu: 49%
Sensory 75% (5% Grade 3/4);  
Motor 9% (0% grade 3/4);  
neuropathic pain 29%  
(1% grade 3/4)
Neutropenia: 28% 
Thrombocytopenia: 3%
Previously untreated patients  
with stages iii/iv FL n = 321  
total (100% FL) n = 162  
for R-CvP arm 
Marcus et al55
R-CvP versus CvP (8 cycles)  
(data presented here for the  
R-CvP arm only)
ORR: 81% CR/CRu:  
41% median TTP: 35 mo
NR Neutropenia: 24%
Abbreviations: FL, follicular lymphoma; ORR, overall response rate; NR, not reported; AE, adverse events; CR/CRu, complete response/complete response unconfirmed; 
NHL,  non-Hodgkin’s  lymphoma;  PFS,  progression-free  survival;  R-CHOP,  rituximab,  cyclophosphamide,  vincristine,  prednisone,  doxorubicin;  R-CvP,  rituximab, 
cyclophosphamide, vincristine, prednisone; TTP, time to progression.
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reason this chemotherapy combination has not gained use 
in follicular lymphoma.
In keeping with the search for both synergistic and safe 
bortezomib-containing combination therapies, the National 
Cancer Institute of Canada Clinical Trials Group completed a 
study of bortezomib and R-CVP in patients with newly diag-
nosed follicular lymphoma requiring treatment. Recognizing 
the morbidities which can be associated with bortezomib-
induced neurotoxicities, and the risk of heightened toxicity 
when combined with a vinca alkaloid, the investigators 
chose a lower bortezomib dose (1.3 mg/m2) and a weekly 
schedule (day 1 and 8).54 They also planned a detailed 
analysis of neurotoxicities, with the incidence of significant 
peripheral neuropathy as a primary endpoint. The complete 
response rate was also a primary endpoint, with a hypothesis 
that the complete response/unconfirmed complete response 
would be at least 56%, a number that was extrapolated from 
the results of the primary R-CVP study for patients with 
relapsed follicular lymphoma in whom complete response/
unconfirmed complete response rates were 41%.55 For the 
94 patients enrolled in this bortezomib plus R-CVP trial, the 
regimen was very well tolerated and 90% of patients com-
pleted the planned eight cycles of treatment. There were no 
grade 4 neurotoxicities and only 5% had grade 3 neurologic 
complications. However, despite this favorable side effect 
profile and overall response rate of 83%, the 49% complete 
response did not meet the primary endpoint predicted to show 
improvement of complete response/unconfirmed complete 
response to 56%.
Bendamustine has recently been approved for use in 
relapsed/refractory follicular lymphoma. In combination 
with rituximab, it is a highly effective regimen, with greater 
than 90% overall response rates in relapsed indolent and 
mantle cell lymphomas.56,57 Unlike the RCHOP/RCVP 
regimens, this agent is not associated with neurologic side 
effects, so bortezomib plus bendamustine may increase the 
efficacy of both agents without limitations from overlapping 
neurotoxicities.
Two Phase II trials of the combination of bortezomib, 
b  endamustine, and rituximab have been completed. In 
the larger VERTICAL study (VELCADE in Relapsed or 
  Refractory Follicular Lymphoma) published by Fowler et al 
Table 4 Clinical trials of bendamustine with or without bortezomib
Population Bortezomib dosing  
schedule
Response rates  
for FL patients  
unless otherwise stated
Toxicities reported as percentage of patients
Neuropathy Gr 3/4 hematologic toxicity
Relapsed/refractory  
indolent B cell NHL  
n = 31 (52% FL)  
Freidberg et al59
Weekly bortezomib  
(1.3 mg/m2) + rituximab- 
bendamustine (90 mg/m2)
ORR 93%; 2 year PFS  
for all patients 47%
Peripheral  
neuropathy: 47% 
(7% Gr 3; 0% Gr 4)
Neutropenia: 17% 
Thrombocytopenia: 17%
Relapsed/refractory  
patients with FL  
with prior rituximab  
exposure n = 73 (100% FL)  
Fowler et al,  
the vERTiCAL study58
Biweekly bortezomib  
(1.6 mg/m2) +  
R-bendamustine  
(50–90 mg/m2)
ORR 88%  
CR 53%  
CR median  
PFS 14.9 months
Peripheral  
neuropathy: 44% 
(11% grade 3,  
0% grade 4)
Neutropenia: 25% 
Thrombocytopenia: 14%
Previously untreated  
low-grade B cell NHL  
n = 513 total (54% FL)  
n = 260 for bendamustine  
arm (53% FL)  
Rummel et al70
R-bendamustine  
(90 mg/m2) versus  
RCHOP (data  
presented here for the  
bendamustine arm only)
CR 40% in all patients Paresthesias: 7% Neutropenia: 11%
Relapsed/refractory MCL  
or low-grade B cell NHL  
n = 63 (38% FL)  
Rummel et al56
Rituximab- 
bendamustine  
(90 mg/m2)
ORR 96% all patients  
CR 71%
0% Leukopenia: 16% of cycles 
Thrombocytopenia:  
3% of cycles
Relapsed/refractory  
indolent B cell NHL  
not-rituximab-refractory  
n = 66 (61% FL)  
Robinson et al57
Rituximab- 
bendamustine  
(90 mg/m2)
ORR 93% for all patients;  
54% CR/CRu
NR Neutropenia: 36% 
Thrombocytopenia: 9%
Abbreviations: Gr, grade; FL, follicular lymphoma; NHL, non-Hodgkin lymphoma; MCL, mantle cell lymphoma; ORR, overall response rate; CR/CRu, complete response/
complete response unconfirmed; AE, adverse event; R-CHOP, rituximab, cyclophosphamide, prednisone, vincristine, doxorubicin; PFS, progression-free survival; NR, not 
reported.
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in 2011, 73 patients with relapsed or refractory   follicular 
  lymphoma were enrolled to receive five 35-day cycles 
of weekly bortezomib, bendamustine, and rituximab 
(375 mg/m2). Bortezomib was administered intravenously 
at a dose of 1.6 mg/m2 on days 1, 8, 15, and 22. This was a 
Phase I/II trial with dose escalation of bendamustine from 
50 mg/m2 to 90 mg/m2. All doses were well tolerated, so the 
90 mg/m2 dose on days 1 and 2 was used in the Phase II expan-
sion study. In the 60 evaluable patients treated at the 90 mg/m2 
dose level of bendamustine, the overall response rate was 
88% (53% complete response) and median   progression-free 
survival was 14.9 months.58 Considering that 47% of the 
patients did not respond to their last treatment and 44% 
were refractory to rituximab, response rates were especially 
encouraging at 89% and 95% in these groups, respectively. 
Based on complete response/unconfirmed complete response 
rates of 56%–60% in trials of bendamustine-rituximab in 
relapsed/refractory indolent non-Hodgkin’s lymphoma,56,57 
the authors had hypothesized that the complete response rate 
with the addition of bortezomib would be over 60%. Though 
the study did not reject the null hypothesis because the com-
plete response rate was ,60%, such a large improvement in 
complete response may have been an ambitious goal, given 
the heavily pretreated nature of this population.
Although most patients were able to receive the planned 
number of cycles (median five cycles) in the VERTICAL 
study, toxicity was high. Sixty-six percent of the 73 patients 
included in the safety analysis experienced grade 3 or 
greater adverse events felt to be drug-related (majority from 
myelosuppression), 30% had dose reductions in therapy, and 
22% (n = 16) discontinued therapy due to adverse events. In 
addition, 12 patients experienced reactivation of herpes zoster 
which prompted investigators to recommend prophylaxis for 
future bortezomib plus bendamustine-rituximab regimens, 
although half of the patients with outbreaks were already on 
antiviral prophylactic medications.
In the other multicenter trial evaluating bendamustine-
rituximab combined with bortezomib, investigators chose a 
biweekly bortezomib dosing schedule, based on evidence of 
better efficacy with this regimen in the single-agent setting. It 
was a smaller study of 31 patients with relapsed or   refractory 
indolent lymphoma and mantle cell lymphoma, and only 
16 patients with follicular lymphoma were included. Patients 
were scheduled to receive six 28-day cycles of bendamus-
tine 90 mg/m2 on days 1 and 4 and rituximab 375 mg/m2 on 
day 1 combined with bortezomib on days 1, 4, 8, and 11.59 
Most of the grade 3 or 4 toxicities were hematologic, with 
five patients (17%) each developing grade 3 or higher 
  thrombocytopenia and neutropenia. Fourteen patients (47%) 
developed peripheral neuropathy, but it was only grade 3 or 
higher in two patients and most symptoms resolved after 
  cessation of treatment. Reactivation of herpes zoster infection 
was also seen, occurring in four patients (13%, no patients 
were on antiviral prophylaxis). The overall response rate 
was as encouraging as the VERTICAL study, with 93% 
partial response and complete response rates observed for 
follicular lymphoma, and an 83% overall response rate for 
all included patients. However, the 2-year progression-free 
survival for all treated patients was 47%, which did not meet 
the primary endpoint of 25% improvement as compared with 
the historical use of bendamustine-rituximab.
Although neither of these trials demonstrated an improve-
ment in response rate or progression-free survival with the 
addition of bortezomib to bendamustine-rituximab, cross-
trial comparisons are difficult to make because of differences 
in trial design. The patients enrolled in the bortezomib-
bendamustine-rituximab trials had more refractory disease 
and were more heavily pretreated than in the bendamustine-
rituximab studies (Table 4). Therefore, by achieving results 
equivalent to those of the bendamustine-rituximab studies, 
one could argue that bortezomib did improve outcomes just 
as easily as concluding that it had little additional benefit. 
In addition, positron emission tomography was not used 
to assess response in the bendamustine-rituximab studies, 
so some responses graded as a complete response might 
have been counted as a partial response if positron emission 
tomography scans had been performed.
The added toxicity from combining bortezomib with 
bendamustine-rituximab is not insignificant, with nearly 
a quarter of patients dropping out of both bortezomib tri-
als because of adverse events and 26%–34% of patients 
experiencing a serious adverse event. In contrast, patient 
withdrawal due to adverse events was extremely uncommon 
in the bendamustine-rituximab studies, at less than 3%. In 
the end, without a randomized controlled trial comparing 
bendamustine-rituximab ± bortezomib, no definite conclu-
sions can be drawn about the benefits of adding bortezomib 
and whether they outweigh the additional risks.
Toxicity including neuropathy
Any treatment decision, particularly in relapsed disease 
where patients have likely already accumulated symptoms 
from previous treatments or the lymphoma itself, must bal-
ance perceived therapeutic benefit with treatment-related 
morbidity and mortality. Though bortezomib is often 
considered safe and well tolerated across patient groups, 
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  including in the elderly,60 the potential for significant 
  toxicities in single-agent or combination regimens should be 
considered. Tables 1–4 include all reported neurotoxicities, 
and grade 3 or 4 non-neurologic toxicities, as reported in the 
trials involving bortezomib in follicular lymphoma.
Classically bortezomib has been associated with periph-
eral sensory neuropathy, with or without accompanying 
painful or burning dysesthesias. This occurred in up to 
74% of patients included in the follicular lymphoma stud-
ies reviewed herein, varying greatly depending upon the 
bortezomib dose, schedule (weekly or biweekly), or if 
used in combination with other chemoimmunotherapies. 
In addition to sensory neuropathy, bortezomib can also be 
associated with a motor neuropathy leading to lower extrem-
ity weakness, or an autonomic neuropathy manifesting 
as orthostatic hypotension or gastrointestinal side effects, 
such as   constipation. For example, when the Baiocchi et al 
rituximab-bortezomib study assessed for sensory, motor, and 
autonomic neuropathy (orthostatic hypotension, constipation/
ileus) they increased their appraisal of grade 3 neuropathy to 
54% from 40% when only considering peripheral neuropa-
thy.41 However, many other single-agent or combination stud-
ies did not include assessment beyond sensory neuropathy 
or neuropathic pain.
Also complicating the assessment of bortezomib-induced 
neuropathy is the frequency of baseline peripheral neuropathy 
for study participants, many of whom had previously been 
exposed to neurotoxic medications, such as vincristine. 
Baseline neuropathy was not well described in all studies, 
though some studies question whether prior vincristine truly 
predicts the development of grade 3/4 neuropathy.41 The 
complexities of clinical or biological factors that increase the 
risk for development of neuropathy while on bortezomib-based 
therapy are not well appreciated from available evidence.
The exact mechanism for bortezomib-induced neuropathy 
is uncertain, though animal based studies have demonstrated 
direct mitochondrial damage in Schwann cells of the sciatic 
nerve and in the dorsal root ganglia. This damage occurs to 
a greater intensity in more distal cells, which correlates with 
the distribution of neuropathic symptoms in the fingers and 
toes in patients.61 It has been suggested that this damage from 
bortezomib occurs upon surpassing a certain threshold dose, 
not from cumulative toxicity,62 and frequently in the studies 
of non-Hodgkin’s lymphoma and multiple myeloma inves-
tigators reported reversal of symptoms after the medication 
was held.42,54,58,63 Many would argue that the best treatment 
for bortezomib-induced neuropathy is prevention and avoid-
ing its use in high-risk patients. Unfortunately, to date, no 
patient subgroup has been definitively linked to development 
of grade 3 or 4 peripheral neuropathy.
From the success and widespread use of bortezomib in 
multiple myeloma, criteria for dose modifications of bort-
ezomib when neuropathy or other toxicities occur have been 
developed.64 These modifications allow for continued thera-
peutic drug dosing while minimizing or reversing symptoms. 
Quality of life assessments will aid in answering whether the 
potential benefit from new bortezomib-containing regimens 
outweighs the increased rates of neuropathy, a critical deter-
mination in an indolent disease such as follicular lymphoma 
where the goal of therapy is generally palliative.
Conclusion and future directions
In conclusion, despite preclinical data and the encouraging 
results of bortezomib in other hematologic malignancies, 
with multiple myeloma shining as the hallmark of its suc-
cess, treatment with bortezomib in follicular lymphoma has 
resulted in diverse response rates as a single agent (overall 
response rate 16%–41%)65 and provided questionable added 
benefit compared with established regimens such as ritux-
imab, R-CHOP, bendamustine-rituximab, or R-CVP. In 
fact, most of the bortezomib combination trials did not meet 
their primary endpoint because of the failure of bortezomib 
to improve responses or survival to the degree anticipated. 
Though various alterations in the bortezomib dosing schedule 
(ie, biweekly) may result in increased response rates, this was 
not always true when it was used in combination with other 
drugs, and biweekly or combination treatment was often also 
associated with an increase in drug-related neurotoxicity. 
Such toxicities are especially limiting in a disease such as 
follicular lymphoma where overall survival is measured in 
years but cure is rarely obtained. Therefore, new therapies 
must not only show tumor response but also justify the 
toxicities of therapy, either by ameliorating disease-related 
symptoms refractory to other effective treatment, prolonging 
time until further therapy is needed, or by increasing overall 
survival. With the current evidence, it is difficult to conclude 
that bortezomib for the treatment of follicular lymphoma 
satisfies these conditions.
The reason for the conflicting and somewhat disappoint-
ing results in follicular lymphoma could be multifactorial, 
from the incorrect extrapolation of in vitro data for the 
mechanism of action of bortezomib in mantle cell lym-
phoma or diffuse large B cell lymphoma cell lines to its 
potential in follicular lymphoma, the oversimplification of 
pathways involved in follicular lymphoma pathobiology, the 
inability of patients to receive full effective treatment doses 
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because of toxicities, or limitations in study design. With 
this recognition, there perhaps still remains potential for 
bortezomib in the treatment of follicular lymphoma.   Better 
randomized trials are planned, such as bortezomib plus 
R-CVP versus R-CVP, and bendamustine-rituximab with or 
without bortezomib,54,59 to eliminate patient disparities and 
other confounding variables discussed in the trials earlier, 
as well as to investigate possible subgroups of patients with 
follicular lymphoma more likely to respond to bortezomib-
containing regimens. In addition, recent evidence has 
demonstrated reduced toxicities of bortezomib when given 
as an injection66 and this may enable patients to complete 
intended therapy with fewer side effects. Other potential 
toxicities may arise if bortezomib is combined with alterna-
tive treatment modalities, such as radioimmunotherapy67 or 
with important intracellular targets for follicular lymphoma 
currently in development, such as NF-κB inhibitors, histone 
deacetylase inhibitors, heat-shock protein 90 inhibitors, or 
pan-Bcl-2 family inhibitors.68 These novel treatment combi-
nations may target important intracellular signaling at more 
than one level for better efficacy, and most importantly may 
reduce treatment-related morbidity and mortality by lower-
ing the required dose of bortezomib, and by providing an 
alternative treatment regimen to the systemic toxicities of 
conventional chemotherapy.
Continued discoveries, such as those discussed above, 
are anticipated to bring promising new targeted treatments 
for follicular lymphoma, and additional evidence on the 
  optimal way to utilize these drugs to affect meaningful patient 
  outcomes. The degree to which bortezomib will be involved 
in these future developments to improve follicular lymphoma 
care is yet to be determined.
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